Insulet Corporation $PODD Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC increased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 41.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,967 shares of the medical instruments supplier’s stock after buying an additional 51,453 shares during the quarter. Hsbc Holdings PLC’s holdings in Insulet were worth $36,921,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Graetz Wealth LLC grew its position in shares of Insulet by 30.2% during the first quarter. Graetz Wealth LLC now owns 1,009 shares of the medical instruments supplier’s stock worth $212,000 after acquiring an additional 234 shares during the last quarter. Azzad Asset Management Inc. ADV lifted its position in Insulet by 13.9% in the 1st quarter. Azzad Asset Management Inc. ADV now owns 16,648 shares of the medical instruments supplier’s stock valued at $3,493,000 after purchasing an additional 2,028 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Insulet by 3.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 166,454 shares of the medical instruments supplier’s stock valued at $34,929,000 after purchasing an additional 5,450 shares during the last quarter. Resona Asset Management Co. Ltd. boosted its stake in Insulet by 1.0% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 22,647 shares of the medical instruments supplier’s stock valued at $4,744,000 after purchasing an additional 234 shares during the period. Finally, Stephens Investment Management Group LLC boosted its stake in Insulet by 26.0% during the 1st quarter. Stephens Investment Management Group LLC now owns 177,707 shares of the medical instruments supplier’s stock valued at $37,290,000 after purchasing an additional 36,655 shares during the period.

Insulet Trading Up 2.0%

Insulet stock opened at $167.37 on Tuesday. The firm has a market cap of $11.59 billion, a price-to-earnings ratio of 38.92, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The firm’s 50 day moving average price is $153.27 and its two-hundred day moving average price is $205.49. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts predict that Insulet Corporation will post 6.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on PODD shares. Benchmark restated a “buy” rating on shares of Insulet in a research report on Wednesday, May 27th. Truist Financial reduced their price objective on Insulet from $219.00 to $210.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Wall Street Zen downgraded Insulet from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Barclays decreased their price objective on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Finally, Stifel Nicolaus cut their target price on Insulet from $250.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $235.25.

Insider Activity

In related news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.36% of the stock is owned by company insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.